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Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens
in health and disease
Rutger A. F. Gjaltema and Ruud A. Bank
MATRIX Research Group, Department of Pathology and Medical Biology, University Medical Center Groningen, University of
Groningen, Groningen, the Netherlands
ABSTRACT
Collagen is a macromolecule that has versatile roles in physiology, ranging from structural sup-
port to mediating cell signaling. Formation of mature collagen fibrils out of procollagen a-chains
requires a variety of enzymes and chaperones in a complex process spanning both intracellular
and extracellular post-translational modifications. These processes include modifications of amino
acids, folding of procollagen a-chains into a triple-helical configuration and subsequent stabiliza-
tion, facilitation of transportation out of the cell, cleavage of propeptides, aggregation, cross-link
formation, and finally the formation of mature fibrils. Disruption of any of the proteins involved
in these biosynthesis steps potentially result in a variety of connective tissue diseases because of
a destabilized extracellular matrix. In this review, we give a revised overview of the enzymes and
chaperones currently known to be relevant to the conversion of lysine and proline into hydroxy-
proline and hydroxylysine, respectively, and the O-glycosylation of hydroxylysine and give
insights into the consequences when these steps are disrupted.
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The extracellular matrix (ECM) is composed of several
macromolecules, such as collagens, fibronectin, elastin,
laminins, hyaluronan and proteoglycans. ECM molecules
are synthesized and secreted locally by specialized cells
predominantly belonging to the mesenchyme lineage
(e.g. (myo)fibroblasts, chondrocytes, osteoblasts, tendo-
cytes). The classical view of ECM function pertains to its
role in supporting tissues, either by maintaining its
form, or by withstanding biomechanical forces. Beyond
this, ECM molecules have roles in a wide variety of
physiological functions, such as cell-cell signaling, adhe-
sion, migration, cell differentiation and many more.
Disruptions in ECM biosynthesis can therefore nega-
tively influence all these processes.
Collagen molecules are composed of three a-chains
that are, at least in part, folded into a triple-helical con-
formation (triple helix). A collagen molecule can be
composed of three a-chains expressed from a single
gene (homotrimers) or from two or three different
genes (heterotrimers) (Figure 1). The 28 known collagen
types can be subdivided into nine families based on
their structural features (Myllyharju & Kivirikko, 2004).
One of these families are the fibril-forming collagens
(type I, II, III, V, XI, XXIV and XXVII). The fibrillar collagen
family can be further subdivided into clade A, B or C
collagens, based on their evolutionary origin (Exposito
et al., 2010). Despite their structural differences, all colla-
gen molecules (irrespective of its type) show stretches
of helical formation of the three a-chains, and these
stretches show repeated Gly-X-Y motifs (where X and Y
can be any amino acid). Due to this resemblance, most
of the collagen types rely on similar biosynthesis
pathways. Biosynthesis of fibril-forming collagens is a
multistep process spanning both intracellular and extra-
cellular post-translational modifications facilitated by
various enzymes and chaperones (Figure 2). Mutations
in several of these enzymes are responsible for a num-
ber of heritable diseases that display extensive collagen
defects (Table 1). In addition, mutations in collagen
genes and aberrant collagen deposition (as a result of
aberrant synthesis, degradation and/or modification)
have also been reported in connective tissue diseases –
as well as in pathologies ranging from fibrosis to cancer
and arthritis.
Collagen molecules show a variety of post-transla-
tional modifications (PTMs), such as hydroxylation of
many Pro and Lys residues into hydroxyproline
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(Hyp) and hydroxylysine (Hyl), and the subsequent gly-
cosylation of Hyl. Even though these collagen PTMs
have been studied in considerable detail in the last two
decades, quite some question marks remain with regard
to, for example, substrate specificities and structure/
function relationships. Emerging evidence indicates that
highly interconnected processes are fundamental to
collagen PTMs. In this review, we present a revised up-
to-date view on which proteins are needed to work
together in an assembly-line fashion for generating
Hyp, Hyl and glycosylated Hyl, and the consequences
these PTMs have on connective tissues.
Hydroxylation of prolyl residues
Prolyl 4-hydroxylation and prolyl 3-hydroxylation
The triple-helical part of collagen molecules consist of
repetitive Gly-X-Y motifs, where the X and Y positions
can contain any amino acid, but mostly are occupied
by a proline (Pro) and a 4-hydroxyproline (4Hyp),
respectively. One of the first steps in post-transla-
tional modification of procollagen is the conversion of
triple-helical Pro into Hyp. The Pro in the telopeptides
are not converted to Hyp because of the lack of the
Gly-X-Y motif. Two enzyme families that reside in the
lumen of the ER catalyze the hydroxylation of helical
proline residues (Figure 3). These are the collagen
prolyl-4-hydroxylases (C-P4Hs), which catalyze proline
4-hydroxylation (4Hyp) at the Y position in the Gly-
X-Y motif of the alpha chains, and the prolyl-
3-hydroxylases (C-P3Hs), which catalyze proline
3-hydroxylation (3Hyp) at the X position in the Gly-
X-4Hyp sequence of the alpha chains. Both families
are 2-oxoglutarate dioxygenases: they need 2-oxoglu-
tarate, O2, ascorbate and Fe
2þ for their activity.
Collagen prolyl-4-hydroxylases: tetrameric proteins
composed of P4H and PDI
The human collagen proyl-4-hydroxylase (C-P4H) is a
tetrameric enzyme composed of two a-subunits and
two b-subunits. The b-subunit is encoded by P4HB; it is
also known as protein disulfide isomerase (PDI). Three
isoforms are known for the a-subunit (designated as a(I),
a(II), and a(III)) that are encoded by P4HA1, P4HA2 and
P4HA3 genes, respectively. The type I, II and III C-P4Hs
are tetramers with the composition [a(I)]2b2, [a(II)]2b2
and [a(III)]2b2, respectively. Tetramers containing a mix-
ture of two types of a-subunits are unlikely to occur
(Annunen et al., 1997; Kukkola et al., 2003a; Van Den
Diepstraten et al., 2003; Vuori et al., 1992a). The a-sub-
unit facilitates substrate recognition and enzymatic
activity. The substrate recognition of C-P4Hs is mostly
performed by the peptide-substrate-binding domain
located at the N-terminus of the a-subunits, whereas the
catalytic domain is located at the C-terminus (Hieta
et al., 2003). After the hydroxylation reaction the affinity
to the peptide-substrate-binding domain weakens and
results in dissociation from the C-P4H (Hieta et al., 2003).
PDI monomers perform disulfide isomerase activity;
however, this activity is not required for C-P4H tetramer
formation or its prolyl 4-hydroxylase activity (Lamberg
et al., 1996; Vuori et al., 1992c). Instead, as the b-subunit
of C-P4Hs, PDI is responsible for retaining the tetramer
in the rER through its C-terminus via its KDEL retention
signal (Vuori et al., 1992b, 1992c). In addition, PDI per-
forms a chaperone function by preventing aggregation
of nascent procollagen chains (Kivirikko & Pihlajaniemi,
1998; Myllyharju, 2003). Also, without the b-subunit the
a-subunit forms aggregates that does not show catalytic
activity (Kivirikko & Myllyharju, 1998; Nietfeld et al.,
1981).
Figure 1. The molecular structure of fibrillar procollagen. Fibrillar procollagens consist of three a-chains that are bundled into a
triple helix. In its mature form, each a-chain consists of a N-terminal and a C-terminal propeptide, adjacent to the N-terminal and
C-terminal telopeptide, respectively. The triple-helical part of the a-chain is situated in the middle. Modification of lysine (K) into
Hyl occurs in the telopeptides and the triple helix, whereas modification of proline (P) into Hyp occurs in the triple-helical part
only. Disulfide bonds (indicated in red) are in most fibrillar collagens only present in the propeptides. Whereas the N-propeptides
of fibrillar collagens contain a short triple-helical sequence the C-terminal propeptides do not display any triple helix formation.
(see color version of this figure at www.informahealthcare.com/bmg.)
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Hydroxylation of proline residues occurs exclusively
on individual unfolded procollagen a-chains. Once the
a-chains are folded in a triple-helical configuration,
C-P4Hs are not able anymore to convert Pro into 4Hyp
(De Jong et al., 1991; Kivirikko et al., 1971). The three
isoforms of P4HA are expressed in a tissue-dependent
manner: P4HA1 is expressed in most tissues, P4HA2 is
the main form in chondrocytes, osteoblasts as well as
endothelial and epidermal cells (Annunen et al., 1998;
Grimmer et al., 2006; Nissi et al., 2001), whereas P4HA3
mRNA has been detected in many tissues, albeit in very
low amounts (Kukkola et al., 2003b). The overall amino
acid sequence identity between the a-subunits is rather
low and ranges between 35% and 65%. The highest
degree of similarity is observed at the C-terminal end,
where the catalytic site is located. Nothing is known
about substrate specificities of the a-subunits in terms
of affinities towards the different collagen types.
Furthermore, two forms of both the a(I) and a(II) subu-
nits are known, due to alternative splicing of P4HA1 and
P4HA2, respectively. It remains to be seen whether
these splice variant products display specific biological
functions.
Consequences of prolyl 4-hydroxylation
4-Hydroxylation of collagen proline residues is essential
for proper assembly and (thermal) stabilization of colla-
gen triple helices through intramolecular hydrogen
bonding (Berg & Prockop, 1973). When collagen prolyl
residues are underhydroxylated, the processed collagen
molecules undergo abnormal assembly, with reduced
thermal stability. In contrast to heterozygotes, P4HA1
null mice show developmental delay and die between
E10.5 and E11.5, presumably caused by ruptured capilla-
ries resulting from a disturbed deposition of the base-
ment membrane-specific collagen type IV (Holster et al.,
2007). Isolated fibroblasts from these null mice were still
able to secrete fibril-forming collagens (type I and III),
but the resulting fibrils show a slightly increased diam-
eter. Interestingly, P4HA2 null mice are viable (discussed
in (Myllyharju & Kivirikko, 2004)). In humans, no muta-
tions are found in the genes coding for any of the P4HA
a-subunits, perhaps indicating that in humans a loss of
C-PH4 enzyme function leads to a premature death of
the embryo. A heterozygous missense mutation in the
C-terminal disulfide isomerase domain of P4HB, affect-
ing disulfide isomerase activity but not prolyl-4-hydrox-
ylation, leads to the osteogenesis imperfecta-like Cole-
Carpenter syndrome (Rauch et al., 2015).
Prolyl-3-hydroxylases
Prolyl-3-hydroxylases (also known as leprecans) are rep-
resented in three isoforms in humans, namely P3H1,
P3H2 and P3H3, which are encoded by LEPRE1, LEPREL1
and LEPREL2, respectively. All contain a similar
N-terminal domain, and a C-terminal 2-oxoglutarate-
dependent dioxygenase domain with hydroxylase activ-
ity that shares homology with prolyl-4-hydroxylases and
lysyl hydroxylases (Vranka et al., 2004). Prolyl 3-hydroxy-
lases have both unique and overlapping distributions in
adult and embryonic tissues (Capellini et al., 2008;
Tiainen et al., 2008b; Vranka et al., 2009). In general,
P3H1 is present at tissues rich in fibrillar collagens,
Figure 2. Biosynthesis of fibrillar collagens at a glance. After
procollagen a-chains are imported into the ER, three individ-
ual a-chains associate to form a triple-helical structure while
simultaneously being subjected to post-translational modifica-
tions of Pro and Lys residues. Trimer formation and folding
into a triple-helical conformation starts with the association of
the carboxyl-terminal propeptides and subsequent formation
of disulfide bonds between the propeptides (I). During these
processes, collagen chaperones prevent aggregation within
the cell or premature association of procollagen chains.
Following transport from the late-Golgi, the N-terminal pro-
peptide can be cleaved from procollagen (II). When deposited
into the extracellular space (III), the triple-helical procollagen
is converted to collagen by cleavage of its remaining C-ter-
minal propeptide (IV). Next, the resulting triple-helical collagen
molecules aggregate into fibrils that are subsequently cova-
lently cross-linked to increase fibril stability (V). (see color ver-
sion of this figure at www.informahealthcare.com/bmg.)
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whereas P3H2 is predominantly seen in basement
membrane-rich tissues (Vranka et al., 2009). P3H1 is
identified as a member of a trimeric complex formed
together with cartilage-associated protein (CRTAP) and
cyclophilin B (CypB) (Vranka et al., 2004), a complex that
hydroxylates the a1(I) Pro986 residue of fibrillar colla-
gen chains a1(I) and a1(II) (Baldridge et al., 2008;
Morello et al., 2006; Weis et al., 2010a). Another complex
that resides in the ER consist of four different proteins,
namely P3H4/P3H3/CypB/LH1, a complex that facilitates
the activity of LH1 (Heard et al., 2016).
Prolyl-3-hydroxylation varies among fibrillar
collagen types and tissue types
3-Hydroxyproline sites within GPP (specifically: Gly-
Pro-4Hyp) sequences have been determined in the
human a1(I), a2(I), a1(II), a1(III) and a2(V) chains. The
following 3Hyp residues were found in these clade A
collagen chains: Pro986 (also denoted as the A1 site;
99% occupancy in a1(I), a1(II), and a1(V); 0% occupancy
in a1(III), no GPP available in a2(I)), Pro944 (also
denoted as the A2 site; 60% occupancy in a2(V),
10–87% occupancy in a1(II), 0% occupancy in a1(I), a2(I)
and a1(III)), Pro707 (also denoted as the A3 site; 80%
occupancy in a2(I) and a2(V), 0% occupancy in a1(I),
a1II) and a1(III)), and Pro470 (also denoted as the A4
site; 13% occupancy in a2(V), 0% occupancy in a1(I),
a2(I) and a1(II), no GPP available in a1(III)) (Fernandes
et al., 2011; Weis et al., 2010b). Especially remarkable is
the complete absence of 3Hyp in collagen type III, and
the full occupation of 3Hyp at position Pro986 in a1(I),
a1(II) and a2(V). 3Hyp has also been found in the (GPP)n
repeat located C-terminal of Pro986 of a1(I), a2(I) and
Table 1. Heritable connective tissue disorders related to mutations in collagen biosynthesis enzymes affecting lysyl or prolyl
hydroxylation.
Enzyme Gene Collagen-related activities Associated genetic disorders
Prolyl 4-hydroxylase 1 (P4HA1) P4HA1 Unknown
Prolyl 4-hydroxylase 2 (P4HA2) P4HA2 4-hydroxylation of proline residues at
the Y position of the Gly-X-Y-Gly
motif
Unknown
Prolyl 4-hydroxylase 3 (P4HA3) P4HA3 Unknown
Prolyl 4-hydroxylase 1 beta
polypeptide (PDI)
P4HB Beta subunit of prolyl-4- hydroxylase
proteins ensures activity of
P4HA1–3; in addition: disulfide
isomerase
Cole–Carpenter syndrome type 1
Prolyl 3-hydroxylase 1 (P3H1) LEPRE1 Osteogenesis imperfecta type VIII
Prolyl 3-hydroxylase 2 (P3H2) LEPREL1 3-hydroxylation of proline residues at
the X position of the Gly-X-4Hyp-
Gly motif; P3H1 complexes with
CRTAP and CypB
Unknown
Prolyl 3-hydroxylase 3 (P3H3) LEPREL2 Unknown
synaptonemal complex 65 (P3H4) SC65 Affects activity of LH1 (but not LH2) Unknown
Cartilage associated protein (CRTAP) CRTAP Complexes with P3H1 and CypB;




Peptidylprolyl isomerase B (CypB) PPIB Complexes with CRTAP and P3H1;
Cofactor for 3Hyp modification and
collagen folding; CypB binds to









FK506 binding protein 22 (FKBP22) FKBP14 Presumed procollagen chaperone No official classification: Ehlers- Danlos
syndrome with progressive kypho-
scoliosis, myopathy, and hearing
los
FK506 binding protein 65 (FKBP65) FKBP10 Procollagen chaperone, LH2
dimerization
Osteogenesis imperfecta type XI,
Kuskokwim syndrome, Bruck
syndrome type 1
Lysyl hydroxylase 1 (LH1) PLOD1 5-hydroxylation of triple-helical lysyl
residues
Ehlers-Danlos syndrome type VIA
Lysyl hydroxylase 2 (LH2) PLOD2 5-hydroxylation of telopeptide lysyl
residues by LH2b; function LH2a
unknown
Bruck syndrome type 2
Lysyl hydroxylase 3 (LH3) PLOD3 5-hydroxy lation of triple-helical lysyl
residues and O- glycosylation of
galactosylhydroxylysine
No official classification: EDS-like
phenotypes
Membane-bound zinc transporter,
member 13 (ZIP 13)
SLC39A13 Affects lysylþ prolyl hydroxylation by
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a1(II) (Eyre et al., 2011). Clearly, there are major differen-
ces in the percentage of 3Hyp site abundance between
the different collagen chains, even though the sites are
homologous. In addition, variations of 3Hyp levels are
seen at the same residue of identical collagen chains
from different tissues. Most strikingly are the differences
in the degree of occupancy of Pro944 by 3Hyp in a1(II)
(highest in the cornea, lowest in articular cartilage,
intermediate in nucleus pulposus) (Weis et al., 2010b)
and in the extreme C-terminal (GPP)n repeat in a1(I) and
a2(I) (high in tendon, absent in skin and bone) (Eyre
et al., 2011) or a1(II) (high in cornea, low in cartilage)
(Hudson et al., 2015). It should be stressed that the
above refers to mammalian species only, as the 3Hyp
patterns can be different in lower invertebrates. For
example, the A1 site of collagen type III is fully hydroxy-
lated in Xenopus and chicken skin, whereas no such
hydroxylation was seen in mammalians. Further dissimi-
larities were already previously discussed (Hudson et al.,
2011).
Specificity of prolyl-3-hydroxylases
P3H depletion experiments have deciphered the sub-
strate specificity of P3H1, P3H2 and P3H3 towards colla-
gen type II and the a2 chain of collagen type V
(Fernandes et al., 2011). The authors demonstrated that
P3H1 is the primary enzyme for Pro986, that P3H2 is
responsible (at least in part) for 3-hydroxylation of
Pro944, Pro707 and the C-terminal (GPP)n repeat, and
that P3H3 is partially involved in the 3-hydroxylation of
Pro707 and the C-terminal (GPP)n repeat. The substrate
specificity of P3H1 and P3H2 towards Pro986 and
Pro707 in collagen type I, respectively, was confirmed in
P3h1 null mice (Pokidysheva et al., 2013a), in mice carry-
ing a single amino acid substitution in the catalytic site
of the P3h1 gene (Homan et al., 2014), and in P3h2 null
mice (Hudson et al., 2015), equivalent to human LEPRE1
and LEPREL1 respectively.
3Hyp residues have also been found in clade B colla-
gen chains, namely a1(V), a1(XI) and a2(XI). Major
hydroxylation sites (25–75% occupancy) are Pro434,
Pro665 and Pro692 (Weis et al., 2010b). However, noth-
ing is known about the substrate specificity of P3H iso-
enzymes towards these clade B collagen chains.
Furthermore, a high number of 3Hyp residues have
been reported for collagen type IV: over 10 residues per
a-chain (Basak et al., 2016). P3H1 does not seem to
hydroxylate collagen type IV, but P3H2 does (Tiainen
et al., 2008b; Hudson et al., 2015).
Consequences of prolyl 3-hydroxylation
Although all three isoenzymes can be found
together, the differences in expression at various
Figure 3. Collagen prolyl hydroxylation. Prolyl (P) 4-hydroxylation at numerous positions is performed by the tetrameric complex
P4HA/PDI, while PDI alone catalyzes disulfide bonds in the propeptides (both reactions indicated by the green arrow). Prolyl
3-hydroxylation is performed by the three different P3H isoforms at a few predetermined locations only. The complex of P3H1/
CypB/CRTAP is responsible for P986 hydroxylation of the a-chains, whereas P3H2 hydroxylates P707 and P944 of the a-chains.
P3H3 also hydroxylates Pro707, and additionally the C-terminal (GPP)n repeat. During these processes CypB performs cis-trans iso-
merization of collagen prolyl peptide bonds, and together with FKBP65 prevents premature association of procollagen a-chains.
(see color version of this figure at www.informahealthcare.com/bmg.)
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developmental stages and some of the unique tissue
specificities suggest major functional roles for each
of the modifications. Indeed, mutations in LEPRE1,
resulting in an absence of hydroxylation of Pro986,
results in severe or lethal autosomal recessive osteo-
genesis imperfecta (Amor et al., 2011; Baldridge
et al., 2008; Marini et al., 2007), whereas mutations
of LEPRE2 results in severe myopia in the absence of
musculoskeletal abnormalities (Guo et al., 2014;
Hudson et al., 2015; Mordechai et al., 2011). The
absence of Hyp986 might lead to decreased colla-
gen-protein interactions, as has been shown for
decorin (Grafe et al., 2014), whose binding is near
the collagen residues 961/962, which is in close
proximity to 986 (Keene et al., 2000).
Based on the position of 3Hyp in the sequence of
fibrillar a-chains, it was postulated that this amino acid
is involved in the lateral association of collagen mole-
cules as well as the D-staggered alignment of molecules
in the initial assembly of collagen fibrils (Hudson et al.,
2011). The outward pointing direction of 3Hyp in the
triple helix (Schumacher et al., 2006) may promote
short-range hydrogen bonding between individual tri-
ple helices, thereby facilitating supramolecular assembly
(Weis et al., 2010b). Tendons from P3h1 null mice show
that the basic molecular packing of collagen molecules
along the fibril axis is the same and that there are no
differences in the D-spacing, but that there is a disor-
dered packing (D-stagger distortions). In new-born
P3h1 null mice, the fibril diameter in tendons is
increased, whereas in adult mice the fibrils are disorgan-
ized due to branching and fuzing, most probably due
to a failure of the postnatal lateral fusion of smaller
fibrils (Pokidysheva et al., 2013b). Interestingly, an
increase in 5-hydroxylysine (Hyl) in its glycosylated form
is seen in skin and tendon of P3h1 null mice (most likely
due to an increased occupancy of normally modified
Hyl, not due to additional modification sites), and espe-
cially in bone. The excess of glycosylation in bone might
have a severe impact on the tight packing and mineral-
ization of collagen, and it has been put forward that
this excess glycosylation results in more severe distur-
bances than the lack of 3Hyp itself (Pokidysheva et al.,
2013b).
Although collagen type IV has the highest number
of 3Hyp residues reported so far in collagens, the
function of 3Hyp in collagen type IV is less under-
stood. Half of these 3Hyp residues are located in the
7S domain (Risteli et al., 1980a). Both collagen type
IV and 3Hyp are ancient molecules, as both are
found in sponges (Boute et al., 1996), which are the
most primitive multicellular organisms of the animal
kingdom.
P3H1 activity requires CRTAP and CypB
Complex formation with CRTAP and CypB is necessary
for P3H1 to perform proline-3-hydroxylation in vivo of
unfolded collagen chains, which is decreased when
either CRTAP or CypB is knocked-out or mutated
(Barnes et al., 2006; Cabral et al., 2007; Morello et al.,
2006). P3H1, CRTAP and CypB form a 1:1:1 complex
(Morello et al., 2006) which is responsible for the
3-hydroxylation of Pro986 (due to P3H1). Mutations in
P3H1 results in the loss of 3Hyp at position 986.
Interestingly, mutations in CRTAP, a protein that shows
strong homology with the N-terminal end of P3H1 (but
lacks the C-terminal catalytic domain), also results in the
loss of 3-hydroxylation of Pro986. Finally, mutations in
CypB result in decreased levels of 3Hyp at position
Pro986, indicating that all components of the complex
contribute to the functioning of P3H1.
The formation of complexes with CRTAP and CypB
has not been confirmed for P3HA2 and P3HA3. Since
there are no differences in 3-hydroxylation other than
the residue Pro986 in osteogenesis imperfecta cases or
null mice (Amor et al., 2011; Chang et al., 2010), and
since coexpression of CRTAP does not influence 3-prolyl
hydroxylase activity of recombinant P3H2 in vitro
(Tiainen et al., 2008a), it is highly plausible that complex
formation with CTRAP and CypB is not needed for P3H2
or P3H3 activity.
Hydroxylation of lysyl residues
Lysyl 5-hydroxylation occurs in the telopeptides
and in the triple-helical part
Lysyl hydroxylases (LHs) are present in the rER where
they catalyze the conversion of lysine (Lys) into 5-
hydroxylysine (Hyl) in the a-chains of procollagen
(Figure 4A). Hyl can be found in the triple helix and in
the telopeptides. Some of these Hyl residues are essen-
tial in the forming of certain covalent cross links; fur-
thermore, Hyl can serve as an attachment site for
carbohydrates, resulting in galactosylhydroxylysine
(GHyl) or glucosylgalactosylhydroxylysine (GGHyl).
Additionally to collagens, LHs are also able to target
other proteins with collagenous sequences, such as adi-
ponectin (Ruotsalainen et al., 2012). Just as the C-P4Hs
and P3Hs, the lysyl hydroxylases belong to the 2-oxo-
glutarate dependent dioxygenases. In humans, as in
rats and mice, three isoenzymes exist: LH1, LH2 and
LH3, encoded by PLOD1, PLOD2 and PLOD3, respect-
ively. The expression of the LH genes is tissue-type
dependent (Mercer et al., 2003a; Passoja et al., 1998;
Walker et al., 2005). All three isoforms are expressed
during embryonic development of mice, but the levels
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of expression vary immense between the isoforms in
different developmental stages. While LH1 is expressed
highly throughout development, LH2 is only highly
expressed until day 7 and LH3 until day 7 and ree-
merges at day 15, showing that the LH genes are specif-
ically regulated during organogenesis (Salo et al.,
2006b).
Hydroxylation of Lys in the triple helix of collagen
occurs exclusively on Lys present in the sequence Gly-
X-Lys; a Lys in the X position is not hydroxylated. The
hydroxylated Lys in the telopeptides is embedded in an
entirely different amino acid sequence. In view thereof,
the existence of two classes of enzymes has been
postulated: a class of enzymes that converts the Lys in
the triple-helical sequence into Hyl (helical lysyl hydrox-
ylase) and a class of enzymes that is responsible for the
conversion of Lys in the telopeptides into Hyl (telopep-
tide lysyl hydroxylase).
The Lys (and consequently Hyl) in the telopeptides
can, after it is converted into allysine or hydroxyallysine
by lysyl oxidases, interact with Lys, Hyl or His in the tri-
ple helix, leading to various divalent and trivalent cross
links (Figure 4B). Here, we restrict ourselves to certain
cross-links derived from Lys and/or Hyl. The cross-link
hydroxylysylpyridinoline (HP) is formed out of two
hydroxyallysine residues from the telopeptides and a
specific Hyl of the triple helix, whereas lysylpyridinoline
is made of two hydroxyallysine from the telopeptides
and a specific Lys of the triple helix. An increase in the
total amount of HP and LP cross-links reflects an
increase in lysyl hydroxylation of the telopeptides; an
increase in HP at the expense of LP reflects an increase
in hydroxylation of the specific Lys residues of the triple
helix that are involved in cross-linking. Likewise, an
increase in LP at the expense of HP reflects a dimin-
ished hydroxylation of the same Lys residues in the
triple helix. The triple-helical Lys of a1(I) involved in
cross-linking is K87 or K930, for a2(I) this is K87 or K933,
for a1(II) this is K87 or K930 and for a1(III) this is K96 or
K939. The N-telopeptide of a1(I), a2(I), a1(II) or a1(III)
cross-links with the aforementioned C-terminal Lys/Hyl
in the triple helix, whereas the C-telopeptide of a1(I),
a1(II) or a1(III) cross-links with the mentioned
N-terminal Lys/Hyl in the triple helix (there is no Lys in
the a2(I) C-telopeptide).
The most direct evidence that a telopeptide lysyl
hydroxylase must exists has been derived from cross-
link studies in Ehlers–Danlos syndrome type VIA and
Bruck syndrome. EDS-VIA patients show a decreased
level of Hyl in the triple helix in certain collagen types
Figure 4. Collagen lysyl hydroxylation and cross-linking. (A) Lysyl hydroxylases (LH) need to form dimers for activity. For LH2,
FKBP65 assists in the dimerization, whereas for LH1 the P3H4/P3H1/CypB complex could potentially drive this dimerization. LH2
specifically performs 5-hydroxylation at both telopeptides regions at K9 a1(I), K5 a2(I) and K1208 a1(I). In collagen type I, LH1
seems to be the predominant isoform responsible for 5-hydroxylation of lysine in the helical domain of the a-chains. Here, it per-
forms 5-hydroxylation of at least K87 a2(I) and K930 a1(I) needed for hydroxylysylpyridinoline cross-linking. (B) Specific 5-hydroxy-
lysine residues are reactive groups towards oxidation reactions that generate pyridinoline cross-links between two K9
residues and one K930 residue, and one K87 and two K1208 residues. (see color version of this figure at www.informahealthcare.
com/bmg.)
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in certain tissues but show a normal level of pyridino-
line or normal excretion levels of pyridinoline in urine
(Acil et al., 1995; Steinmann et al., 1995). Pyridinoline is
a cross-link derived from the hydroxyallysine route.
Thus, in EDS-VIA, despite the deficiency of Hyl in the tri-
ple helix, a normal amount of Hyl is present in the telo-
peptides. From this, it follows that the mutated gene in
EDS-VIA is a helical lysyl hydroxylase. In Bruck syn-
drome, the opposite is seen: in bone, normal Hyl levels
of the triple helix in collagen are seen, whereas hydrox-
yallysine-derived cross-links (relying on telopeptide Hyl)
are virtually absent (Bank et al., 1999a). Thus, in Bruck
syndrome, despite normal levels of triple-helical Hyl, a
deficiency of Hyl in the telopeptides is observed, show-
ing the existence of a telopeptide lysyl hydroxylase. The
gene mutated in EDS-VIA is PLOD1 (Hyland et al., 1992;
Yeowell & Walker, 2000), indicating that LH1 is a helical
lysyl hydroxylase, whereas the lysyl hydroxylase
mutated in Bruck syndrome is PLOD2 (Ha-Vinh et al.,
2004; Puig-Hervas et al., 2012; van der Slot et al., 2003;
Zhou et al., 2014), indicating that LH2 is a telopeptide
lysyl hydroxylase.
Substrate specificity of LH1 and LH3
Despite normal pyridinoline levels in EDS-VIA patients,
the ratio of HP to LP has changed dramatically as LP is
formed at the expense of HP. This indicates that the tri-
ple-helical Lys residues involved in cross-linking colla-
gen (a1(I): K87 or K930; a2(I): K87 or K933; a1(II) K87 or
K930; a1(III): K96 or K939) are not hydroxylated, mean-
ing that LH1 specifically hydroxylates these residues
and that LH3 (or LH2) is not able to compensate for
this. In normal tissues, most of the Lys residues in colla-
gen IV and V are hydroxylated, whereas the lysyl
hydroxylation levels of collagen types I and III is much
less. Mutations in LH3 gives rise to 30% lower Hyl levels
in a preparation of collagens IV and V, whereas no such
decrease is seen in a preparation containing collagen I
and III (Ruotsalainen et al., 2006). Thus, LH3 does not
seem to play a major role in the lysyl hydroxylation of
collagen I and III. Indeed, no differences were found in
the HP/LP ratio of bone (Ruotsalainen et al., 2006), indi-
cating that the Lys residues in collagen type I that par-
ticipate in crosslinking are not hydroxylated by LH3.
This is in agreement with the observation that a loss of
LH1 leads to a replacement of HP by LP, showing that
LH1 is primarily involved in hydroxylating the triple-hel-
ical Lys residues involved in cross-linking (Steinmann
et al., 1995).
The observation that the triple-helical regions of col-
lagens II, IV and V are hydroxylated normally in EDS-VI
patients, whereas collagen types I and III are not,
already suggested the presence of two lysyl hydroxy-
lases with different substrate specificities (Ihme et al.,
1984), as was the finding that the residual lysyl hydroxy-
lase activity of EDS-VIA cells preferentially hydroxylated
type IV collagen (Risteli et al., 1980b). From the available
data, it seems that LH1 hydroxylates mostly lysine in
the triple-helical region of collagen I and III (especially
the residues involved in cross-linking), and that LH3
hydroxylates mostly lysine in the triple-helical region of
collagen types II, IV and V. However, this does not
explain why EDS-VIA patients show differences in the
triple-helical lysyl hydroxylation of collagen type I
derived from various tissues. Here, collagen type I from
skin and bone in EDS-VIA is Hyl deficient, whereas colla-
gen type I from tendon, kidney and lung is not (Ihme
et al., 1984). This observation still waits an explanation.
The above data show that LH3 cannot compensate
for the loss of LH1 in the case of collagens I and III, and
that the other lysyl hydroxylases cannot compensate for
the loss of LH3 in the case of lysyl hydroxylation of col-
lagen type IV and V. The loss of LH1 and LH3 activity
does not lead to a decreased level of pyridinoline cross-
linking, showing that neither enzyme is involved in the
lysyl hydroxylation of the N- and C-telopeptides (only
Hyl in the telopeptides can generate pyridinoline cross-
links). This job seems to be restricted to LH2.
Substrate specificity of LH2
LH2 has two splice forms, LH2a (short) and LH2b (long),
that result from alternative splicing of PLOD2, with
LH2b containing an additional exon 13A of 63 bps
encoding 21 amino acids. LH2b is ubiquitously
expressed in almost all tissues examined, whereas LH2a
is only expressed in lower amounts and always together
with LH2b in kidney, liver, spleen, placenta and cartilage
(Salo et al., 2006a; van der Slot et al., 2004; Walker et al.,
2005; Yeowell & Walker, 1999). Inclusion of exon 13A is
tissue-specific and depends on the expression of
RBFOX2, TIA1 and TIAL1 proteins that mediate splicing
towards LH2b by binding to intronic cis-elements flank-
ing exon 13A (Seth & Yeowell, 2010, Venables et al.,
2013; Walker et al., 2005; Yeowell et al., 2009).
Suppression of these trans-acting factors by siRNAs
decreased the levels of LH2b (long) and increased the
levels of LH2a (short). Recently, also exonic cis-enhancer
elements were found inside exon 13A that regulate
splicing of LH2 via a currently unknown trans-acting
protein factor (Seth et al., 2011). Whole tissue splicing
patterns of LH2 changes during embryogenesis of mice.
Until E11.5 LH2a is the main isoform present, where the
expression of LH2b starts at E11.5 being the main iso-
form from then on (Salo et al., 2006a).
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LH2b is mostly seen in tissues rich in fibrillar colla-
gens, whereas LH2a is mostly absent in such tissues.
Expression studies in (precursors of) osteoblasts have
revealed that the elevation of Lys hydroxylation in the
telopeptides of type-I collagen coincides with a higher
expression of LH2 mRNA (Uzawa et al., 1999), suggest-
ing that LH2b is a telopeptide lysyl hydroxylase. This
was indeed confirmed in later studies (Mercer et al.,
2003b; Pornprasertsuk et al., 2004; van der Slot et al.,
2003, 2004). The absence of LH2b has a major impact
on musculoskeletal tissues, especially bone, as illus-
trated by mutations in PLOD2. So far, nine mutations
have been found in PLOD2, resulting in Bruck syndrome
type 2 as well as an autosomal recessive form of osteo-
genesis imperfecta (Ha-Vinh et al., 2004; Puig-Hervas
et al., 2012; van der Slot et al., 2003; Zhou et al., 2014).
All mutations are located in the C-terminal part of
PLOD2 and are located between exon 12 and 19 (Zhou
et al., 2014). The absence of LH2 activity results in
decreased levels of pyridinoline in bone. An elevated
expression of LH2b has been recognized as a general
phenomenon in fibrotic conditions of various tissues,
where specifically LH2b is correlated with elevated lev-
els of pyridinoline cross-links per collagen since LH1
and LH3 do not show a similar increased expression
(van der Slot et al., 2004). These two examples describe
an important role for LH2b in the formation of collagen
telopeptide-derived pyridinoline cross-links.
Whether LH2b is also able to hydroxylate triple-hel-
ical Lys is an as yet unanswered question.
Unfortunately, the hydroxylation status of the triple
helix has never been investigated in Bruck syndrome
type-2 patients, but the Lys residues in the triple helix
are hardly affected in Bruck syndrome type-1 patients
(characterized by FKPB10 mutations). Upregulation of
LH2b by a variety of cytokines resulted in a substantial
increase in hydroxylation of the telopeptides, but not in
the triple helix (van der Slot et al., 2005). It thus seems
likely that LH2b only hydroxylates the telopeptides. On
the other hand, coexpression of LH2b with proa1(I) in
insect cells resulted in a substantial amount of Hyl resi-
dues in the triple helix as was the case for LH1 and LH3.
In this expression system only LH2b was able to hydrox-
ylate the N-telopeptide; hydroxylation of the C-telopep-
tide was not investigated. Addition of LH1 and LH2b in
vitro to nonhydroxylated a1(I) as produced in Pichia
pastoris resulted in comparable amounts of triple-helical
Hyl (Takaluoma et al., 2007). In addition, LH2b is able to
hydroxylate synthetic peptides exhibiting sequences
derived from the triple helix (Risteli et al., 2004;
Takaluoma et al., 2007). Interestingly, LH2b was not able
to hydroxylate the a1(I) N-telopeptide in a peptide
sequence format (as was the case for the C-telopeptide),
but it was able to do so when the N-telopeptide
sequence was present in the proa1(I) procollagen chain
(Takaluoma et al., 2007). It thus seems that LH2b some-
how requires the collagenous domain in order to
hydroxylate the telopeptides.
Even less is known about LH2a. Since it is mainly
absent in tissues rich in fibrillar collagens, it does not
seem to play a role in lysyl hydroxylation of fibrillar col-
lagens. Of the nine reported mutations of LH2, eight
affect both transcripts, that is, the mutations can have
an effect on both LH2a and LH2b. One mutation specif-
ically affects the splicing, and the patient only
expressed LH2a but not LH2b (Puig-Hervas et al., 2012).
As the presence of LH2a (which replaces LH2b) leads to
Bruck syndrome, this indicates that LH2a is not able to
hydroxylate the telopeptides. However, the evidence for
this statement is only indirect, as cross-link studies have
not been performed, and expression analysis of LH2a in
bone was not conducted.
Lysyl hydroxylases are only active as dimers
All three lysyl hydroxylases need to form homodimers
for lysyl hydroxylase activity whereas this is not obliga-
tory for the glucosyltransferase activity of LH3
(Heikkinen et al., 2011; Rautavuoma et al., 2002).
Interestingly, dimerization between different isoforms
was observed in vitro where LH3 was able to form a het-
erodimer with LH1 (Heikkinen et al., 2011). However,
there was a much higher tendency to form homodimers
than heterodimers. We have shown that LH2a and LH2b
also can form a heterodimer with LH1 and LH3, but that
LH2a cannot form a heterodimer with LH2b (Gjaltema
et al., 2016). The ability to form heterodimers could
broaden the specificity of the performed lysyl hydroxy-
lase reactions for different collagens, and might partly
explain the striking differences in lysyl hydroxylation
levels between the different collagen types or the same
collagen type between different tissues.
P3H1 and CypB influence lysyl hydroxylase activity
Strangely, mutations in proteins other than LHs can
affect lysyl hydroxylation. Transgenic mice carrying a
single amino substitution in the catalytic site of P3h1
did not show evidence of a generalized over-modifica-
tion of collagen type I. The total amount of HPþ LP was
the same, but there was an increase in the HP/LP ratio.
This ratio reflects the hydroxylation status of K87 and
K930 in a1(I) and/or K87 and K933 in a2(I) that partici-
pates in cross-link formation. Since the hydroxylation
status of K87 and K930 in a1(I) was unaltered, the differ-
ence in HP/LP ratio may be due to an increased
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hydroxylation at the homologous sites in the a2(I) chain
(Homan et al., 2014). If so, the observation is still diffi-
cult to explain, as the triple-helical cross-link sites of
a1(I) and a2(I) are both hydroxylated by LH1. Is there a
role of P3H1 in this phenomenon by affecting specific
LH1 activities?
CypB also seems to interact with LH1, thereby having
a positive effect on LH1 activity (Boudko et al., 2012;
Ishikawa et al., 2012). A mutation of CypB in horses suf-
fering from hyperelastosis cutis resulted in a decrease in
Hyl and Glc-Gal-Hyl in skin and tendon, despite a delay
in folding of procollagens in the rER (Ishikawa et al.,
2012). A delay in folding normally results in an overmo-
dification. A dramatic decrease in Hyl was confirmed in
skin of CypB null mice (Cabral et al., 2014), whereas the
amount of GHyl and GGHyl remained the same. A less
striking decrease in Hyl levels, but still significant, was
found in tendons (Terajima et al., 2016), and the per-
centage of GHyl and GGHyl was higher, indicating
an overmodification of the existing Hyl residues.
Interestingly, in bone there was no decrease in Hyl,
GHyl was increased, and GGHyl was, as Hyl, unchanged.
A more detailed analysis of bone collagen type I
revealed a systematic underhydroxylation of triple-hel-
ical Lys involved in cross-linking (a1(I)K87, a2(I)K87,
a2(I)K933), whereas most of the triple-helical Lys resi-
dues that are not involved in cross-linking are normally
hydroxylated or overhydroxylated. As a consequence,
the ratio LP/HP in bone increased (Cabral et al., 2014).
An increased ratio of urinary LP to HP has also been
reported in hyperelastosis cutis horses (Ishikawa et al.,
2012), again indicating an underhydroxylation of the
bone triple-helical Lys involved in cross-linking. A pref-
erential underhydroxylation of a1(I)K87 and a2(I)K87
was also found in tendons and, interestingly, an
increase in the hydroxylation of the N- and C-telopepti-
des was observed in the CypB null mice (Terajima et al.,
2016). It was shown with immunoprecipitation that
CypB interacts with LH1, LH2 and LH3; the modification
patterns in CypB mice show that CypB somehow regu-
lates the function of LHs.
SC65 influence LH1 but not LH2 activity
Interestingly, also the protein synaptonemal complex
65 (SC65¼ LEPREL4¼ P3H4) plays a role in lysyl hydrox-
ylation. It forms a complex with P3H3, CypB and LH1.
The absence of P3H4 does not affect the lysyl hydroxyl-
ation level in the telopeptides but results in severe
under-hydroxylation of the helical-domain lysines that
control whether HP of LP cross-links are formed, result-
ing in increased levels of LP at the expense of HP. Thus,
P3H4 is required for the activity of LH1, but not LH2
(Heard et al., 2016). Since LH1 is only active as a dimer,
this means that either the P3H4/P3H3/LH1/CypB com-
plex is of a pentameric nature, or the P3H4 complex
assists in LH1 dimerization as has recently been
observed for FKBP65 in LH2 dimerization (Gjaltema
et al., 2016).
FKBP65 influences lysyl hydroxylase activity
Another protein that indirectly affects lysyl hydroxyl-
ation, namely in the telopeptides, is FKBP65, encoded
by FKBP10. The N- and C-telopeptides of a1(I) were spe-
cifically underhydroxylated in FKBP10 null mice, while
there were no differences in the helical domain
(Lietman et al., 2014). Interestingly, postnatal FKBP10
expression is limited to bone and ligament, reflecting
the bone and contracture phenotype of Bruck syn-
drome (Lietman et al., 2014). Bruck syndrome type 1
and some autosomal recessive cases of OI are caused
by mutations in FKBP10 (Alanay et al., 2010; Bank et al.,
1999a; Barnes et al., 2012, 2013; Caparros-Martin et al.,
2013; Kelley et al., 2011; Shaheen et al., 2010, 2011;
Steinlein et al., 2011; Venturi et al., 2012 Zhou et al.,
2014). Intriguingly, the phenotype is similar to that of
Bruck syndrome type 2 that is caused by mutations in
PLOD2. Both syndromes show the same biochemical
defect, namely a strong underhydroxylation of the telo-
peptides of collagen type I (Bank et al., 1999a; Barnes
et al., 2012, 2013; Schwarze et al., 2013), resulting in a
pyridinoline content that is 5–10% of that in control
bone. In contrast, in all of the human subjects a normal
or a slight increase in the hydroxylation of the triple-
helical Lys residues is seen (Bank et al., 1999a; Barnes
et al., 2012, 2013; Schwarze et al., 2013). Remarkably, in
a patient with a FKBP65 null mutation, a HP:LP ratio of
3.7:1 was observed, whereas in control bone this ratio
was 2.6:1 (Schwarze et al., 2013), despite the fact that
peptide mapping showed a normal lysyl hydroxylation
level of a1(I)87 and a1(I)930 of the non-crosslinked pep-
tides. Schwarze et al. (2013) explained this by postulat-
ing that the few hydroxyallysines in the telopeptides
show preferential bonding to Lys over Hyl of the par-
tially hydroxylated triple-helical sites. However, what
makes this explanation less likely is the normal HP:LP
ratio seen in bone of a case described by Bank et al.
(1999), the case that showed the c.344G>A
(p.Arg114Gln) point mutation in FKBP10 (Schwarze
et al., 2013). Another remarkable observation is, that
collagen type I in ligaments showed a normal pyridino-
line crosslink level (Bank et al., 1999a), as was the case
for collagen type II in cartilage (Bank et al., 1999a;
Schwarze et al., 2013). It thus seems that FKBP65 is
required for LH2b activity in bone tissue, but not in
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other tissues, although such a mechanism is difficult to
explain.
A deletion of Tyr293 in the third PPIase domain of
FKBP10 has been found in the autosomal recessive
Kuskokwim syndrome (Barnes et al., 2013), a disorder
found in Yup’ik Eskimos living around the Kuskokwim
River (Alaska, USA). This syndrome is characterized by
congenital contractures of large joints with spinal, pel-
vic and foot deformities but with only minor skeletal
manifestations. It thus extends the phenotypic spec-
trum of FKBP10 from OI alone, and OI with contractures
(Bruck syndrome), to a predominantly congenital con-
tracture syndrome. A residual (2–10%) lysyl hydroxyl-
ation of the telopeptide Lys1208 residue was observed,
and patients with a 2%-3% residual telopeptide hydrox-
ylation had more severe skeletal symptoms than that of
patients with 8%-10% hydroxylation. This residual lysyl
hydroxylation might explain the minor skeletal features
of the Kuskokwim syndrome compared to Bruck syn-
drome (Barnes et al., 2013), where an essentially
undetectable hydroxylation of Lys1208 is seen. It has
been postulated that the impaired telopeptide hydrox-
ylation perhaps disturbs the specific linear secretion
and deposition through fibripositors of collagen in ten-
dons (a distinctive pathway for tendons), explaining the
congenital contractures.
We have recently shown that FKBP65 forms a com-
plex with LH2 but not with LH1 and LH3, and that inhib-
iting the PPIase activity of FKBP65 prevents the
formation of LH2 dimers. As only dimers show lysyl
hydroxylase activity, this explains why mutations in
FKBP65 have such a dramatic impact on LH2 (Gjaltema
et al., 2016). Surprisingly, also CypB can bind to LH2, as
well as to FKBP65. However, in contrast to FKBP65,
CypB seems to inhibit LH2 activity, as an absence of
CypB results in higher hydroxylation levels of the telo-
peptides (Terajima et al., 2016).
SLC39A13 is involved in collagen modification
The gene encoding the membrane-bound zinc trans-
porter ZIP13 (SLC39A13) is mutated in the spondylo-
cheiro-dysplastic type of EDS (Giunta et al., 2008). These
patients have an increased lysyl pyridinoline/hydroxyly-
syl pyridinoline (LP/HP) ratio in the urine, indicating
that the triple-helical lysyl residues involved in cross-
linking are underhydroxylated. Collagen produced by
fibroblasts showed an overall underhydroxylation of Lys
residues of the triple helix (i.e. it was not confined to
the triple-helical Hyl involved in cross-linking), and also
lower levels of 4Hyp and 3Hyp. Thus, hydroxylation of
collagen as a whole was generally lower. It is not known
how ZIP13 is involved in this process, but it has been
hypothesized that a zinc deficiency in the ER leads to a
more general ER dysfunction rather than reducing the
hydroxylase activity of the prolyl- and lysyl hydroxylases
(Jeong et al., 2012).
Glycosylation of Hyl residues
Two glycosylated forms of Hyl
The heterogeneity of collagen is also markedly
enhanced by O-glycosylation of Hyl via the 5-hydroxyl
group with a monosaccharide (b-D-galactopyranose,
Gal) or a disaccharide (a-D-glucopyranosyl-(1->2)-b-D-
galactopyranose, GlcGal). Thus, two glycosylated forms
of Hyl exist: galactosylhydroxylysine (GHyl) and gluco-
sylgalactosylhydroxylysine (GGHyl). The first step, the
addition of galactose to Hyl, is catalyzed by glycosyl
transferase 25 domain 1 (GLT25D1) and glycosyl trans-
ferase 25 domain 2 (GLT25D2), whereas the second
step, the addition of glucose on GHyl, is catalyzed by
LH3, finally resulting in GGHyl (Figure 5).
GLT25D1 and GLT25D2 catalyze the formation of
GHyl
Glycosyl transferase 25 domain 1 (GLT25D1) and glyco-
syl transferase 25 domain 2 (GLT25D2) are rER localized
enzymes that show high hydroxylysine galactosyltrans-
ferase activity toward collagen and mannose binding
lectin (Liefhebber et al., 2010; Schegg et al., 2009).
The distribution of these two collagen b(1-
O)galactosyltransferase enzymes is tissue-dependent;
GLT25D1 is expressed in almost all tested human adult
and fetal tissues except for tissues belonging to the ner-
vous system, whereas GLT25D2 is expressed specifically
in the nervous system (Schegg et al., 2009). Whether
both enzymes target similar substrates is currently
unknown. Both enzymes contain three DXD (Asp-any
residue-Asp) sugar-binding motifs, but only the first two
motifs (amino acids 166–168 and 461–463) are needed
for galactosyltransferase activity in GLT25D1 (Perrin-
Tricaud et al., 2011). Based on their overall homology, it
is likely that the same motifs are responsible for the
activity of GLT25D2. Reducing GLT25D1 expression
(31–67%) via RNA interference resulted in a concomi-
tant (35–65%) decrease in total collagen galactosyl-
transferase activity. Interestingly, GLT25D1 and
GLT25D2 failed to show any significant glucosyltransfer-
ase activities. As recombinant GLT25D1 and GLT25D2
had high galactosyltransferase activities towards dena-
tured (deglycosylated) collagen a-chains (Schegg et al.,
2009), GLT25D1 and GLT25D2 are considered the major
contributors to galactosylate hydroxylysine residues of
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collagens prior to LH3 glucosylation of these galactosyl-
hydroxylysine residues. This was confirmed by the
observation that in bone, collagen type I galactosylation
of Hyl is carried out by GLTD1 whereas the subsequent
glucosylation is performed by LH3 (Sricholpech et al.,
2011; Yamauchi & Sricholpech, 2012).
Based on the specific colocalization of GLT25D1
with other rER specific proteins (Liefhebber et al.,
2010), it is highly likely that galactosylation of colla-
gen hydroxylysine residues by these two enzymes
occurs in the early protein secretory pathway, even
before the transport of procollagen to the Golgi
apparatus. Indeed, GLT25D1 showed a comparable
subcellular localization as LH3, and of one of its sub-
strates mannose binding lectin (Liefhebber et al.,
2010). A protein that is similar to GLT25D1 and
GLT25D2 in terms of sequence identity and domain
organization is the cerebral endothelial cell adhesion
molecule (CEECAM1). However, no collagen glycosyl-
transferase activity could be detected (Liefhebber
et al., 2010; Perrin-Tricaud et al., 2011), most likely
due to the incomplete second DXD domain (Perrin-
Tricaud et al., 2011).
LH3 catalyzes the formation of GGHyl
The glycosyltransferase activity of LH3 is located in the
N-terminus of the molecule, whereas the LH activity
resides in the C-terminal part (Heikkinen et al., 2000;
Rautavuoma et al., 2002; Wang et al., 2002a, 2002b).
A loss of glycosyltransferase activity of LH3 does not
affect its lysyl hydroxylase activity. From a phylogenetic
point of view, LH3 is by far the oldest of the three LH
iso-enzymes (Ruotsalainen et al., 1999, 2001), while dur-
ing evolution LH1 and LH2 lost the glycosyltransferase
activity seen in LH3.
Although galactosyltransferase activity for LH3 has
been detected in vitro (Wang et al., 2002a), the galacto-
syltransferase activity of LH3 in vivo is much lower than
its glucosyltransferase activity (Rautavuoma et al., 2002).
It thus seems that LH3 does not play a significant role
in the formation of GalHyl in collagen. Indeed, LH3 null
mice tissues show unaltered enzymatic galactosyltrans-
ferase activities (Rautavuoma et al., 2004), indicating the
presence of other enzymes with such activities. These
other enzymes are most likely the aforementioned
GLT25D enzymes, as LH1 and LH2 do not show any gly-
cosyltransferase activity (Heikkinen et al., 2000;
Rautavuoma et al., 2002; Wang et al., 2002b). In this
context, it is of interest to note that a deficiency of LH3
activity leads to a decrease in urinary GGHyl levels, but
not GHyl levels (Salo et al., 2008).
The combination of lysyl hydroxylase and glysosyl-
transferase activity in a single enzyme is not unique
for LH3. A bifunctional lysyl hydroxylase and glyco-
syltransferase enzyme has been discovered in mimivi-
rus, a giant virus recovered from Acanthamoeba
polyphaga, namely the protein encoded by L230
open reading frame (LR230 ORF) (Luther et al., 2011).
Interestingly, L230 ORF transfers glucose to Hyl,
whereas in the animal kingdom, ranging from
sponges to humans, galactose is transferred to Hyl.
So far, glucosylhydroxylysine has only been found in
viral collagenous sequences.
Figure 5. Glycosylation of hydroxylysines and collagen assembly. Hydroxylysines can be subjected to successive glycosylation. First,
GLT25D1 or GLT25D2 converts 5Hyl into galactosylhydroxylysine (GHyl). Afterwards, LH3 converts GHyl into glucosylgalactosylhy-
droxylysine (GGHyl). During and after addition of the various PTMs, collagen folding occurs from the C-terminus to
N-terminus during which FKBP65 and HSP47 control the aggregation. (see color version of this figure at www.informahealthcare.
com/bmg.)
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Biological roles of glycosylated hyl
The biological significance of collagen glycosylation is
still under investigation. The presence of GHyl in the
a1(IV)1263–1277 region results in a dramatic reduction
of melanoma cell adhesion, as it inhibits CD44 binding
(Lauer-Fields et al., 2003). Glycosylation of Hyl in the
sequence a1(IV)531–543 also results in significant inhib-
ition of melanoma cell a3b1 integrin binding
(Stawikowski et al., 2014). As melanoma cell adhesion to
basement membranes (which are rich in collagen type
IV) is a critical step in the onset of metastasis, one may
conclude that glycosylation of collagen type IV dimin-
ishes tumor cell invasion.
The collagen receptor Endo180 (uPARAP) is involved
in the endocytic uptake of collagen. It was found that
the CTLD-2 lectin domain of Endo180 binds to glycosy-
lated Hyl, leading to an increased endocytic efficiency
of Endo180 toward highly glycosylated collagen (such
as collagen type IV). Remarkably, binding of collagen to
the mannose receptor (MRC1¼CD206), being another
collagen receptor involved in the endocytic uptake of
collagen and a member of the same protein family as
Endo180, is not influenced by glycosylated Hyl
(Jurgensen et al., 2011). The other two family members
of Endo180, namely the phospholipase A2 receptor and
DEC-205, do not directly bind to collagen (Jurgensen
et al., 2014). As Endo180 is involved in collagen turn-
over during malignant progression (Curino et al., 2005),
it seems that glycosylation of Hyl enhances tumor cell
invasion, which is opposite to the finding presented
above with regard to melanoma cell invasion.
Glycosylated Hyl is also important in the induction of
collagen-induced arthritis. Immunization with undergly-
cosylated collagen type II results in a lower severity of
collagen-induced arthritis (Michaelsson et al., 1994;
Myers et al., 2004), and a subset of T cells specifically
recognized glycosylated Hyl (Backlund et al., 2002;
Corthay et al., 1998).
The presence of Hyl is not required for collagen fibril
formation, as collagen devoid of Hyl is able to form
native-type fibrils (Myllyharju et al., 2000; Nokelainen
et al., 2001). However, glycosylated Hyl has an effect on
fibril diameter: increased glycosylation levels results in
thinner fibrils (Batge et al., 1997; Brinckmann et al.,
1999). Hyl or glycosylated Hyl does not seem to have an
effect on the thermal stability of collagen (Nokelainen
et al., 1998).
There are major differences in the glycosylation sta-
tus of Hyl in position a1(I)87. In bovine bone and skin
and in mouse bone more than 90% of the Hyl is glyco-
sylated. However, the ratio GGHyl to GHyl in bovine
bone is 1:5, in mouse bone 3:1, and in bovine skin 1:1.
In rat, tail tendon less than 10% of the Hyl in a1(I)87 is
glycosylated, in a GGHyl to GHyl ratio of 1:1 (Perdivara
et al., 2013). Thus, there are tissue-specific differences in
the glycosylation status of a1(I)87, but there are also
species-specific differences within the same tissue. In
addition, within the same tissue, the glycosylation pat-
tern of homologous sites on the a1(I) and a2(I) chains
differ markedly (Sricholpech et al., 2012): a1(I)87 is a
major glycosylation site, whereas a2(I) is hardly glycosy-
lated. For a1(I)174 and a2(I)174, the situation is
reversed. Impairment of the glucosylation reaction
(carried out by LH3) on GHyl results in a faster self-
aggregation of collagen molecules and in thicker fibrils.
In addition, alterations are seen in cross-link formation
and maturation, as well as a delayed mineralization of
the collagen fibrils (Sricholpech et al., 2012; Terajima
et al., 2014).
It has been postulated that glycosylated Hyl is posi-
tively involved in the binding of DDR2 to collagen
(Bhadriraju et al., 2009; Vogel et al., 1997), as DDR2 was
unable to bind to collagen that was treated with peri-
odate to deglycosylate collagen. However, periodate
also oxidases unsubstituted Hyl, and it is likely that this
oxidation is the reason for not binding of DDR to colla-
gen, rather than the absence of glycosylated Hyl
(Leitinger, 2014).
Mutations in the glycosyltransferase domain of LH3
has major implications for the formation of collagen
type IV and VI structures, both collagens normally being
highly glycosylated. Lack of glycosyltransferase activity
of LH3 in mice results in early lethality because of a
defective basal membrane (Ruotsalainen et al., 2006;
Sipila et al., 2007) due to the diminished secretion of
collagen type IV and defects in the assembly of collagen
IV tetramers in the extracellular matrix. An absence of
the lysyl hydroxylase in Caenorhabditis elegans and
Sophophora (possessing glycosyltransferase activity) is
also lethal because of a lack of basement membranes
(Bunt et al., 2011; Norman & Moerman, 2000).
Furthermore, in mice, defects in tetramer formation of
collagen VI as a consequence of the lack of glycosylated
Hyl was obvious (Sipila et al., 2007), and in addition,
defects were seen in the extracellular aggregation and
distribution of collagen VI. Tetramer formation of colla-
gen VI takes place in the cell itself and is a unique prop-
erty of this collagen type. Outside the cell collagen VI
aggregates into higher-order structures, namely beaded
microfibrillar networks. In man, mutations of LH3 have
been found in two families (Risteli et al., 2009; Salo
et al., 2008), resulting in a syndrome of congenital mal-
formations severely affecting many connective tissues
with skin blisters that resemble epidermolysis bullosa.
In zebrafish, it has been shown that the presence of
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LH3 is critical for motor axon migration and neural crest
cell migration (Banerjee et al., 2013; Schneider &
Granato, 2006).
Knockout studies in mice have revealed that the lack
of glucosyltransferase activity of LH3 causes embryonic
lethality, whereas the lack of LH activity of LH3 resulted
in a normal embryonic development (Ruotsalainen
et al., 2006). Since galactosyltransferase activity of LH3
is likely to be minimal, it shows that the glucosylation
of galactosylhydroxylysine by LH3 has a major func-
tional role. Interestingly, a reduction of LH3 leads to
changes into the cytoskeletal structure, most likely
because of the impaired extracellular matrix organiza-
tion (Risteli et al., 2009).
In addition to the ER, LH3 is found in the extracellular
space as well, in serum, and at the cell surface where it
seems to associate with collagenous proteins (Salo
et al., 2006c). Secretion is dependent on LH3 glucosyl-
transferase activity; secretion into the cell medium was
nearly eliminated when this active site was mutated.
Two pathways for active LH3 secretion have been iden-
tified, either via a Golgi-dependent or a Golgi-independ-
ent mechanism (Wang et al., 2012). The exact function
of extracellular LH3 glycosyltransferase activity is not
completely understood, although differences are
reported in cell growth and viability when there is an
extracellular deficiency of LH3 (Wang et al., 2009).
Interestingly, LH3 was able to modify (hydroxylate and
glycosylate) extracellular proteins in their native con-
formation in vitro (Salo et al., 2006c). Wang et al. specu-
late an extracellular role of LH3 in regulating cell
behavior via cell–matrix interactions or receptor activa-
tion, but the LH3-binding partners are yet to be
identified.
Regulation of collagen folding
Procollagen folding rate affects the level of lysyl
and prolyl hydroxylation
Already during post-translational hydroxylation of pro-
line and lysine residues and glycosylation of hydroxyly-
sines, three selected alpha chains associate at the
C-terminus (in most collagens) and are connected by
disulfide bonds induced by PDI. Triple helix formation
continues from the carboxy-terminus in a zipper-like
fashion towards the amino-terminus (Figure 5).
Hydroxylation of Pro into 3Hyp and 4Hyp, hydroxylation
of Lys into Hyl, and subsequent glycosylation of Hyl
into GHyl or GGHyl occurs on the nascent a-chains.
Once the chains are folded into a triple helix, the
enzymes responsible for these modifications cannot
catalyze their reactions anymore. As a correct
functioning of collagen molecules in the extracellular
space is to a large extent determined by the quality as
well as quantity of the aforementioned post-transla-
tional modifications, it is clear that a correct rate of fold-
ing of procollagen is of considerable importance.
Slowing down the collagen folding rate, for example,
due to mutations in the collagen a-chains, results in
overmodification, as is seen in osteogenesis imperfecta.
During the process of synthesis and triple helix for-
mation, cis-trans isomeration of peptide bonds are cata-
lyzed by peptidyl-prolyl cis-trans isomerases (PPIase). In
fact, the rate-limiting step of triple-helix formation of
collagen is the cis-trans isomerization of peptide bonds.
So far, three PPIases have been reported to act on pro-
collagen. These are FK506-binding protein 22 (FKBP22,
encoded by FKBP14), FK506 binding protein 65 (FKBP65,
encoded by FKBP10) and cyclophilin B (CypB, encoded
by PPIB) (Ishikawa & Bachinger, 2013b; Ishikawa et al.,
2015). FKBP22 and FKBP65 are members of the immu-
nophilins, a group of proteins that exhibit PPIase activ-
ity and that can bind to immunosuppressive drugs such
as FK506 and rapamycin (Sirolimus).
Immunophilins hardly affect procollagen folding
rate
FKBP22 binds to collagen types III, VI and X, but not to
collagen types I, II or V (Ishikawa & Bachinger, 2014). It
seems to prefer 4Hyp (Boudko et al., 2014; Ishikawa &
Bachinger, 2014), so this chaperone likely acts mainly
after prolyl-4-hydroxylation has taken place. Substrates
other than collagen have so far not been reported for
FKBP22. Mutations in, or a complete absence of, FKBP22
results in Ehlers-Danlos syndrome that resembles the
kyphoscoliotic type (Aldeeri et al., 2014; Baumann et al.,
2012; Murray et al., 2014). The substrate specificity of
FKBP22 fits with the observed phenotypes; bone and
articular cartilage are not affected in these patients,
which is in agreement with the observed lack of bind-
ing of FKBP22 to types I, II or V collagen.
Another PPIase that associates with collagen is
FKBP65. A role of FKBP65 as a molecular chaperone of
collagen by assisting in protein folding via the conver-
sion of cis- to trans-isomers of peptidyl-prolyl bonds
seems attractive. Such a chaperone function for FKBP65
has been described for tropoelastin (Davis et al., 1998).
However, the PPIase activity of FKBP65 does not seem
to be as important for the formation of the procollagen
triple helix, as inhibitors of the PPIase activity of FKBP65
had only a marginal effect on the rate of folding of the
triple helix (Bachinger et al., 1993; Zeng et al., 1998).
Also, mutant FKBP65 does not result in collagen over-
modification (i.e. higher levels of (glycosylated) Hyl).
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In addition, it does not affect the normal 3-hydroxyl-
ation of Pro986 of the a1(I) chain (Alanay et al., 2010;
Barnes et al., 2012; Schwarze et al., 2013; Lietman et al.,
2014), suggesting that it acts after the prolyl-3-hydroxyl-
ation complex (Duran et al., 2015).
FKBP65 interacts both with unfolded a-chains (gel-
atin) and triple-helical collagen, and it is able to delay
fibril formation in vitro (i.e. it inhibits collagen aggrega-
tion) (Ishikawa et al., 2008). Therefore, it is assumed that
FKBP65 prevents premature association between pro-
collagen chains during synthesis, as well as premature
aggregation between triple-helical procollagen mole-
cules. This chaperone function of FKBP65 is not inhib-
ited by FK506 or cyclosporin A, whereas both drugs
inhibits its PPIase activity, indicating that PPIase activity
is not involved in the chaperone function (Ishikawa
et al., 2008). Interestingly, FKBP65 initiates coacervation
of tropoelastin, a chaperone function that is also inde-
pendent of its PPIase activity (Cheung et al., 2010; Miao
et al., 2013). Homozygous knock-down of the FKBP10
gene in mice is lethal. Secretion of collagen was not
delayed, but intracellular trafficking was abnormal as
cells contained a dilated ER with embedded matrix as
well as intracytoplasmic collagen fibers (Lietman et al.,
2014), hence indicating the chaperoning function of
FKBP65. In the human situation, type-I procollagen
aggregates are either seen (Alanay et al., 2010) or not
seen (Schwarze et al., 2013). As in null mice, the secre-
tion of collagen was normal or only slightly delayed
(Alanay et al., 2010; Barnes et al., 2012, 2013; Schwarze
et al., 2013); trimerization and folding rate were normal
as well (Barnes et al., 2012).
Cyclophilin B affects procollagen folding rate
CypB has PPIase activity toward collagen both in its free
form and in the P3H1/CRTAP/CypB complex form
(Ishikawa et al., 2009). PPIase activity of CypB is mark-
edly higher than that of FKBP22 or FKBP65. Since the
rate-limiting step of triple-helix formation of collagen is
the cis-trans isomerization of peptide bonds, CypB is
involved in the speed of triple helix formation. Almost
all CRTAP and P3H1 mutations result in overmodifica-
tion of the collagen helical region (i.e., a delayed folding
of the procollagen chains is seen due to a decreased
peptidyl-prolyl cis-trans isomerase activity), indicating
that these components of the complex in turn contrib-
ute to the functioning of CypB. Indeed, the PPIase activ-
ity of CypB is highest when it forms a complex with
P3H1 and CRTAP (Ishikawa et al., 2009), revealing an
interdependence of the complex members. About 16%
of the Pro and 8% of the Hyp in nascent collagen type I
show the cis-configuration (Sarkar et al., 1984).
Inhibition of the activity of CypB by means of cyclo-
sporin A disrupted the stability, folding and assembly of
collagen, showing that the cis-bonds must be converted
into the trans-bonds (Bachinger et al., 1993; Steinmann
et al., 1991). Although CypB has long been attributed as
the only collagen isomerase, the observation that an
absence of CypB can result in a normal helical modifica-
tion (indicating normal folding), favors the hypothesis
that there is more than one collagen isomerase (Barnes
et al., 2010). It seems the P3H1/CRTAP/CypB complex
acts as a molecular chaperone during collagen synthesis
(Ishikawa & Bachinger, 2013a) and behaves as a disul-
fide isomerase in the rER (Ishikawa & Bachinger, 2013b).
Alternative roles for CypB are suggested as a retro-
translocator of abnormal folded collagen to facilitate
proteasomal degradation in the cytosol, a role that was
discovered in CypB null mice, which show abnormally
localized collagen in the ER consistent with a delay in
processing or translocation for proteasomal degradation
(Choi et al., 2009). Finally, CypB seems to be involved in
the initiation of triple helix formation via the folding of
the C-propeptides of type-I collagen (Pyott et al., 2011).
Pathological consequences of aberrations in
prolyl and lysyl hydroxylation
Several heritable connective tissue diseases result in
aberrations of prolyl and lysyl hydroxylation of fibrillar
collagens, due to mutations in collagen (and subse-
quent problems in folding rate of the a-chains), to
mutations in lysyl hydroxylases or prolyl hydroxylases,
or due to mutations in proteins that somehow affect
the activity of one of the hydroxylases (Table 1). Also
acquired diseases, such as osteoporosis, osteoarthritis,
tendinitis, cancer and fibrosis, show changes in the
quality of the collagen molecules, mainly because of
altered lysyl hydroxylation levels.
The kyphoscoliotic type of Ehlers–Danlos syndrome
(EDS-type VIA) is caused by mutations in PLOD1.
Mutations in SLC39A13 (Giunta et al., 2008), PLOD3 (Salo
et al., 2008) and FKBP14 (Aldeeri et al., 2014; Baumann
et al., 2012; Murray et al., 2014) have also been corre-
lated to EDS-like phenotypes. The first is now classified
as the spondylocheiro-dysplastic type of EDS, whereas
the latter has not yet been officially classified as EDS
subtype.
Osteogenesis imperfecta (OI) is a heterogeneous her-
itable connective tissue disorder manifested by low
bone mass and strength that result in bone fragility,
deformity and growth defects. The underlying cause of
OI is directly related to a deficiency of normal collagen
type I deposition in the ECM. The mildest and most
prevalent form of the autosomal dominant OI types
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result from diminished synthesis of structurally normal
procollagen type I caused by heterozygous mutations
in either the COL1A1 or the COL1A2 gene. The more
severe to lethal forms of the autosomal dominant OI
types result from structural defects of the procollagen
type I chains (Wenstrup et al., 1990). Genetic disruptions
in several noncollagen genes have currently been iden-
tified that result in an autosomal recessive OI pheno-
type (Martinez-Glez et al., 2012) (reviewed by (Byers &
Pyott, 2012; Eyre & Weis, 2013; Forlino & Marini, 2016));
six of these loci (LEPRE1, CRTAP, PPIB, SERPINH1, FKBP10
and BMP1/mTLD) seem to have a central function in col-
lagen type I biosynthesis.
Bruck syndrome is a rare autosomal recessive dis-
order characterized as osteogenesis imperfecta with
congenital joint contractures. Bruck syndrome is subdi-
vided into two types that are phenotypically indistin-
guishable, and classification is rather based on
underlying genetic mutations. Bruck syndrome type 1 is
caused by mutations of FKBP65 encoded by KFBP10
(Alanay et al., 2010; Kelley et al., 2011; Moravej et al.,
2015; Schwarze et al., 2013; Setijowati et al., 2012;
Shaheen et al., 2011; Zhou et al., 2014), whereas Bruck
syndrome type 2 is due to mutations in LH2 encoded
by PLOD2 (van der Slot et al., 2003; Ha-Vinh et al., 2004;
Puig-Hervas et al., 2012; Zhou et al., 2014). In contract
to OI, Bruck syndrome patients show normal secretion
of collagen type I, and no mutations in COL1A1 or
COL1A2 are detected (Breslau-Siderius et al., 1998). The
molecular background of Bruck syndrome development
is a reduction in trifunctional cross-linking of collagen
type I caused by an under-hydroxylation of lysyl resi-
dues in the telopeptides but with normal helical lysyl
hydroxylation (Bank et al., 1999a). It is LH2 that hydroxy-
lates the telopeptides. FKBP65 is required to form
dimers of LH2, being the active form of LH2 (Gjaltema
et al., 2016). A disease related to Bruck syndrome is
Kuskokwim syndrome, in which FKPB65 is mutated as
well (Barnes et al., 2013). In this syndrome, the congeni-
tal contractures of large joints are prominent, but in
contrast to Bruck syndrome, there are only minor skel-
etal manifestations.
Apart from heritable connective diseases, changes in
prolyl hydroxylation and lysyl hydroxylation/glycosyla-
tion are seen in various common pathologies. For
example, an increased lysyl hydroxylation/glycosylation
of the triple helix is seen in osteoarthritic cartilage
(Bank et al., 2002; Yang et al., 1991, 1993), in osteopenia
(Batge et al., 1997) and in tendinitis (Bank et al., 1999b),
resulting in an impairment of the functional integrity of
the extracellular matrix. An increase in pyridinoline
cross-linking (due to the increased lysyl hydroxylation
of the telopeptides) is seen in fibrosis, and has been
associated with a decreased degradability of collagen,
thus contributing to the accumulation of collagen and
the irreversibility of scarring (Ricard-Blum et al., 1993;
van der Slot et al., 2004; van der Slot-Verhoeven et al.,
2005). Furthermore, an increase in pyridinoline facili-
tates metastasis of tumor cells (Eisinger-Mathason et al.,
2013; Chen et al., 2015; Gilkes et al., 2013). These are
only some examples of collagen modifications in non-
heritable pathologies, illustrating the major impact of
collagen modifications in health and disease.
Conclusions
Spanning many intracellular and extracellular post-
translational modifications, the path from a single
collagen a-chain to a supramolecular fibril structure
is both complex and fragile. With so many proteins
required to work together in order to form a single
end product, failure to comply can result in a variety
of inherited and acquired diseases. Collagen prolyl
and lysyl hydroxylation can be traced back to one of
the first steps on the evolutionary ladder of complex
multicellular organisms, thus underlining its signifi-
cance. A few of these genes have no known human
pathology since no inheritable mutations are known,
suggesting that they are essential for embryonic
development. Null mice of several collagen biosyn-
thesis-related genes confirm their importance in the
early steps of development. Science is just starting
to understand the individual implications at the bio-
chemical and molecular levels, and a deepened
knowledge of collagen biosynthesis in general and
hydroxylation in particular can make important con-
tributions to treatments in major fields such as can-
cer, fibrosis and regenerative medicine.
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